Waters Corporation (WAT) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong financial performance, particularly in industrial and pharma segments, with positive growth across end markets. The company raised its sales and EPS guidance, suggesting optimism. Despite some concerns about operating margins and conservative growth assumptions, the overall sentiment is positive due to strong market positioning, innovation, and new product launches. The management's confidence in addressing challenges, along with strategic initiatives like the BD acquisition synergy plan, further supports a positive outlook for stock price movement.
Key Financial Performance
Sales Growth Sales grew 9% as reported and 8% in constant currency. This growth was driven by mid-single-digit growth in instruments, high single-digit growth in LC and mass spec portfolio, and 11% growth in recurring revenue, which included 9% service growth and double-digit chemistry growth.
Non-GAAP Earnings Per Share (EPS) Non-GAAP EPS was $2.95, up 12% year-on-year. This increase was attributed to strong sales performance and operational execution.
GAAP Earnings Per Share (EPS) GAAP EPS was $2.47. The reasons for the difference between GAAP and Non-GAAP EPS were not specified.
Pharma Segment Growth Pharma grew low double digits, driven by strong instrument replacement activity and new product adoption, particularly among large pharma and CDMO customers.
Industrial Segment Growth Industrial grew 6%, supported by strong growth in food and environmental testing.
Academic and Government Segment This segment declined low single digits, but performed better than expected.
Chemistry Revenue Chemistry revenue grew 16%, benefiting from approximately $8 million of sales pulled forward in the second quarter related to tariff dynamics.
Gross Margin Gross margin for the quarter was 58.3%, reflecting the impact of regional sales mix and margin dilution from tariff surcharges.
Adjusted Operating Margin Adjusted operating margin was 29.1%, influenced by regional sales mix and tariff surcharges.
Free Cash Flow Free cash flow was $159 million after funding $23 million of capital expenditures. The company also made a $120 million U.S. tax reform payment and paid other items totaling $20 million.
Net Debt Position Net debt position at the end of the quarter was $1.1 billion.
Regional Growth Europe grew 8%, Asia grew 14% (driven by double-digit growth in China, India, and Japan), and the Americas grew 2% (with low double-digit pharma growth partially offset by softness in TA and academic and government).
Instrument Sales Instrument sales grew 4%, led by high single-digit growth in LC and MaxPeak systems.
Service Revenue Service revenue grew 9%, contributing to the overall recurring revenue growth.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Alliance iS sales: Grew 300% year-over-year in the quarter.
Xevo TQ Absolute platforms: Grew 40% and continue to lead the market with exceptional robustness and sensitivity.
MaxPeak premier columns: Grew north of 30% in Q2.
BioResolve Protein A Affinity Columns: Recently launched, marking the first set of affinity columns brought to market in bioseparations.
Empower with light scattering: Ahead of target and customer sales are already coming in.
India revenues: Grew in the high teens.
GLP testing revenue: Grew 70% year-over-year in the first half of 2025.
PFAS testing revenue: Grew over 50% year-over-year in the first half of 2025.
Service plan attachment: Risen 200 basis points to 52% in the first half of 2025.
E-commerce adoption: Now comfortably above 40% of chemistry revenue.
CDMO penetration: Increased to 27% of pharma revenue.
Pending combination with BD Biosciences and Diagnostic Solutions: Expected to accelerate entry into high-growth adjacencies and extend execution model into high-volume segments. Combined company projected to achieve 7% top-line and mid-teens adjusted EPS annualized CAGR growth.
Cost synergies from BD acquisition: $200 million expected by year 3, driven by manufacturing, commercial infrastructure, and procurement savings.
Revenue synergies from BD acquisition: $290 million expected by year 5, driven by commercial excellence, high-growth adjacencies, and cross-selling.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff and Trade Policy Variability: The company faces continued variability in tariffs and the trade policy environment, which could impact financial performance. The tariff impact outlook for the second half of 2025 remains unchanged, and there is uncertainty about future tariff rates.
Macroeconomic Sensitivity in TA Division: The TA division experienced a 6% decline due to softness in macro-sensitive segments such as materials and polymer testing in the Americas and Europe. This indicates vulnerability to broader economic conditions.
Supply Chain and Manufacturing Costs: The company faces challenges related to regional sales mix and margin dilution from tariff surcharges, which impacted gross margin in the quarter. Freight lane optimization and direct procurement savings are areas being targeted for cost reduction.
Regulatory and Export Restrictions: The U.S. export ban on flow cytometry products to China and other regulatory hurdles have impacted growth in BD Biosciences and Diagnostic Solutions. Although export licenses have been reinstated, regulatory risks remain a concern.
Pharma Drug Discovery and ANG Funding: Softness in pharma drug discovery and a 40% decline in U.S. academic and government (ANG) funding through 2027 are expected to impact growth. The company has taken a conservative approach to growth rate assumptions in these areas.
Integration Risks with BD Biosciences and Diagnostic Solutions: The pending combination with BD Biosciences and Diagnostic Solutions involves significant integration challenges, including achieving $345 million in adjusted EBITDA synergies and aligning operational and commercial infrastructures.
Microbiology Business Underperformance: The microbiology segment of BD Diagnostics has underperformed competitors by 180 basis points in revenue growth CAGR from 2019 to 2024. This presents a challenge in uplifting its commercial execution and operational performance.
Currency Exchange Rate Fluctuations: The company’s financial performance is subject to risks from currency exchange rate fluctuations, which could impact reported sales and earnings.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Full Year 2025 Sales Growth Guidance: The company has raised its full year 2025 constant currency sales growth guidance to 5.5% to 7.5% and reported sales growth guidance to 5% to 7%.
Full Year 2025 Non-GAAP EPS Guidance: The company has raised its full year 2025 non-GAAP EPS guidance to $12.95 to $13.05, representing approximately 9% to 10% growth.
Third Quarter 2025 Sales Growth Guidance: The company expects constant currency sales growth of 5% to 7% and reported sales growth of 4.5% to 6.5%.
Third Quarter 2025 EPS Guidance: The company anticipates adjusted earnings per fully diluted share to be in the range of $3.15 to $3.25, representing approximately 8% to 11% growth.
BD Biosciences and Diagnostic Solutions Growth Projections: The company expects the BD Biosciences and Diagnostic Solutions business to return to positive growth in the second half of 2025, with growth rates of 4.5% in 2026, 5% in 2027, and mid-single-digit plus growth in 2028 and beyond.
Revenue Synergies from BD Acquisition: The company projects $290 million in revenue synergies over five years, driven by commercial excellence, high-growth adjacencies, and cross-selling opportunities.
Cost Synergies from BD Acquisition: The company expects $200 million in cost synergies by year 3, representing under 5% of the combined company's cost base.
Combined Company Growth Projections: The combined company is expected to achieve a 7% revenue CAGR and mid-teens adjusted EPS growth CAGR between 2025 and 2030.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the growth rate of the Waters segment instruments, and what factors are contributing to this growth?
A:The Waters segment instruments grew high single digits, driven by growth in LCMS across pharma and industrial segments. The replacement cycle in pharma is progressing as planned, with strong replacement activity in large pharma customers in the U.S. and Europe, as well as growth in the CDMO and genetics customer bases. Alliance iS grew 300% compared to the same quarter last year. Additionally, PFAS testing and the introduction of the TQ Absolute XR instrument contributed to growth.
Q:What is the timeline for introducing new products in the microbiology segment, and what is the potential market size?
A:The timeline for introducing new products in the microbiology segment is estimated to be 2-3 years at the earliest and 4-5 years at the latest. The total addressable market (TAM) is approximately $400 million to $500 million.
Q:What are the expectations for LCMS growth in the back half of the year, and what factors are influencing this outlook?
A:The company expects LCMS growth to continue, supported by strong replacement cycles in large pharma, CDMOs, and genetics. The TQ Absolute XR instrument has exceeded expectations, with significant improvements in robustness and performance. The company has been conservative in its assumptions for the back half of the year, with a 5% instrument growth assumption.
Q:How did the China market perform, and what are the expectations for the rest of the year?
A:China grew double digits this quarter, with strength across all end markets. The industrial segment grew double digits due to success in the battery segment, while the pharma segment also grew double digits, driven by CDMOs. The academic and government segment grew high single digits, supported by localization of the portfolio and a modest stimulus impact. The company remains conservative for the back half of the year, assuming low to mid-single-digit growth and modest stimulus impact.
Q:What factors contributed to the operating margin being lighter than expected, and what is the outlook for margins in the second half of the year?
A:The operating margin was lighter due to geographical mix and costs associated with tariff remediation. The tax rate also contributed to an EPS headwind. Margins are expected to progressively improve in Q3 and Q4, with volume leverage contributing to Q4 improvement.
Q:What is the impact of pull-forward revenue on the guidance for the second half of the year?
A:The company identified $8 million of pull-forward revenue in the quarter. It is assumed that this amount will come out evenly from Q3 and Q4, but it may not impact this year at all.
Q:What is the outlook for the academic and government (ANG) segment, and how is it performing in different regions?
A:The ANG segment declined 3% globally but performed ahead of expectations. In China, it grew high single digits due to portfolio localization and a modest stimulus impact. The company remains conservative for the back half of the year, assuming a high single-digit decline globally.
Q:What are the key drivers of the $290 million synergy plan from the BD acquisition, and how will they be implemented?
A:The synergy plan includes instrument replacement, service attach rate improvement, and e-commerce expansion. These initiatives are expected to have an immediate impact. Additional opportunities include leveraging a larger service and commercial team for LCMS and diagnostics, and taking microbiology into QA/QC and sterile testing laboratories. The plan assumes a straight-line approach over five years.
Q:What is the performance and outlook for the drug discovery business within the pharma end market?
A:The drug discovery business, which is about 5% of pharma revenue, remains slow. Biotechs and CROs are also slow, and the replacement cycle has not kicked in for these segments. However, large pharma and CDMOs are experiencing healthy replacement cycles and growth.
Q:What is the impact of tariffs on the business, particularly in India?
A:The company has not seen any impact from tariffs on the generics business in India. Customers are ramping up capacity, particularly for semiglutide generics and upcoming patent cliffs. The expectation is that tariffs, if implemented, will not significantly impact the generics community, which contributes to lowering medicine costs in the U.S.
Q:What are the revenue synergies from the commercial excellence initiatives, and how are they distributed between biosciences and diagnostics?
A:Instrument replacement is largely on the biosciences side, while e-commerce potential and service attach rate improvements are spread across both biosciences and diagnostics.
Q:What makes the company confident in addressing underperformance issues in the microbiology business?
A:The company has identified pricing and operational initiatives as key areas for improvement. The BACTEC launch is expected to command better pricing, and service attach and e-commerce initiatives are expected to drive additional penetration. Gross margin improvement plans are already in motion, and the company plans to accelerate these efforts.
Q:What is the outlook for LCMS growth in the back half of the year, and what factors are influencing this outlook?
A:The company expects LCMS growth to continue, supported by strong replacement cycles in large pharma, CDMOs, and genetics. The TQ Absolute XR instrument has exceeded expectations, with significant improvements in robustness and performance. The company has been conservative in its assumptions for the back half of the year, with a 5% instrument growth assumption.
Q:What is the outlook for the China market, and what factors are contributing to its performance?
A:The China market is expected to grow low to mid-single digits in the back half of the year. Key drivers include increasing CDMO activity, strength in the battery segment, and localization of the portfolio. The company remains conservative in its assumptions, despite strong performance in the current quarter.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer to the question about the specific impact of tariffs on the business, particularly in India. While they stated that customers have not seen any impact and are ramping up capacity, they did not provide detailed data or clarity on how potential tariffs might affect the business in the future.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ANG
BACTEC
BD Bioscience
BD Biosciences
Biosciences Diagnostic
Diagnostic Solutions
Empower
Europe Asia
LLC
QA QC
Research Division
Waters
center
channel
combination
cost base
cost synergy
creation opportunity
diagnostics
disease
drug discovery
flow cytometry
government
infrastructure
integration
lab
microbiology value
model
opportunity BD
pharma drug
platform
procurement saving
solution
supply
tariff
upside
WAT Transcript
Waters Corporation (WAT) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-3
Waters Corporation (WAT) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings call summary indicates strong financial performance with better-than-expected revenue and operating margins. The Q&A section reveals optimism in growth areas like microbiology and LC-MS, and strategic localization efforts in China. Despite some uncertainties in management's responses, the overall sentiment is positive, with revenue synergies and disciplined cost management. The guidance reflects cautious optimism, and the company's strategic initiatives suggest potential for continued growth, leading to a positive outlook for the stock price.
Waters Corporation (WAT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-2
Waters Corporation (WAT) Q4 2025 Earnings Call Transcript
Positive2-9
The earnings call indicates strong financial performance with 11% EPS growth and optimistic future guidance. The transition to subscription models and new product launches are expected to drive growth. Despite some challenges in BD assets, management is confident in achieving synergies and improving execution. The Q&A section reveals cautious optimism, with a focus on pricing discipline and operational improvements. Overall, the positive guidance, strong EPS growth, and strategic initiatives suggest a positive stock price movement over the next two weeks.
WAT Slides
WAT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
